Fibronectin and lipoprotein(a) are inversely related to plasminogen activator inhibitor type-1 levels in type 2 diabetic patients without complications

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 13, Issue 5, 2000, Pages 269-275

  Testa, R ^a   Bonfigli, A R ^a   Sirolla, C ^a   De Grazia, G ^a   Compagnucci, P ^a   Manfrini, S ^a   Fumelli, D ^a   Testa, I ^a  

^a INRCA   (Italy)

Author keywords

Diabetes mellitus; Fibronectin; Lipoprotein(a); Plasminogen activator inhibitor type 1

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BIOLOGICAL MARKER; FIBRONECTIN; INSULIN; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE MARKER; ENDOTHELIUM; ENDOTHELIUM LESION; FEMALE; FIBRINOLYSIS; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; METABOLIC BALANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; REGRESSION ANALYSIS; STRESS;

BLOOD GLUCOSE; CHOLESTEROL; COMPARATIVE STUDY; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; FEMALE; FIBRONECTINS; FRUCTOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMAN; LIPOPROTEIN(A); MALE; MIDDLE AGE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REFERENCE VALUES; REGRESSION ANALYSIS; TISSUE PLASMINOGEN ACTIVATOR; TRIGLYCERIDES;

EID: 0033776429     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells
2. Plasminogen activator inhibitors
3. Attenuated fibrinolysis and accelerated atherogenesis in Type II diabetic patients
4. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients
5. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis
6. Contrasting fibrinolytic responses in type 1 (insulin dependent) and type II (non insulin dependent) diabetes
7. Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70 year old men
8. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein
9. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia
10. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose
11. The defence against free radicals protects endothelial cells from hyperglycemia-induced plasminogen activator inhibitor 1 over-production
12. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus
13. Serum lipoprotein(a) is increased in hypertensive NIDDM patients
14. Hypercoagulability and high lipoprotein(a) levels in patients with type 2 diabetes mellitus
15. The effect of obesity on fibrinolytic activity and plasma lipoprotein(a) levels in patients with type 2 diabetes mellitus in Korea
16. Relationship of plasminogen activator inhibitor-1 with plasma insulin, glucose, triglycerides and cholesterol in Chinese patients with diabetes
17. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients
18. Tissue-type plasminogen activator inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)
19. Serum levels of lipoprotein(a) in patients with well controlled non insulin dependent diabetes mellitus
20. Plasminogen activator inhibitor: A risk factor for myocardial infarction in diabetes mellitus
21. Relationship between plasminogen activator inhibitor type I plasma levels and the lipoprotein(a) concentrations in non insulin dependent diabetes mellitus
22. A significant relationship between plasminogen activator inhibitor type-1 and lipoprotein(a) in non-insulin-dependent diabetes mellitus without complications
23. Lipoprotein(a): Structural implications for pathophysiology
24. Lipoprotein(a) as a risk factor for coronary heart disease
25. Lipoprotein(a) fibrin binding, and plasminogen activation
26. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue type plasminogen activator. In vitro studies in plasma milieu
27. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients
28. Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels
29. Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a)
30. Elevated plasma levels of ED1+ (″cellular″) fibronectin in patients with vascular injury
31. Plasma levels of von Willebrand factor and fibronectin as marker of persisting endothelial damage in preeclampsia
32. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
33. Admission criteria for immunogerontological studies in man: The SENIEUR protocol
34. Multicenter evaluation of commercially available methods for the immunological determination of plasminogen active or inhibitor-1 (PAI-1)
35. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions
36. Thrombogenic and fibrinolytic factors and cardiovascular risk in non insulin dependent diabetes mellitus
37. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study
38. Insulin resistance and thrombosis: A cardiologist's view
39. Lipoprotein(a): Intrigues and insights